Elan's Panoject Minifusor
This article was originally published in The Gray Sheet
Executive Summary
Two versions of the miniaturized modular infusion pump are granted 510(k) clearance, the Athlone, Ireland-based company announces May 19. Model 100 provides continuous drug delivery therapies while Model 200 is for continuous plus patient controlled analgesia. The ambulatory intravenous or subcutaneous infusion devices utilize Elan's Electro-Transport Drug Administration System (ETDAS) technology ("The Gray Sheet" Jan. 14, 1991, I&W-3) and "can be used for a variety of regimens to include pain management, insulin delivery, chemotherapy, antibiotic, anti-emetic, anticoagulation, tocolytic, AIDS, and chelation therapies," the company says. Since the system will be sold with empty cartridges which will be filled by the pharmacist or physician, FDA approval for use with specific drugs is not necessary. Panoject Minifusor was developed through Elan Medical Technologies Ltd., a joint venture with the Swiss company Pharmasys
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.